Your Global Forum to Accelerate GPCR Drug Discovery Beyond GLP-1 

Advancing Small Molecules, Peptides & Antibodies to Drug Novel GPCRs in Multiple Indications with Improved Selectivity, Safety & Efficacy 

The GPCR field is experiencing a renaissance, driven by renewed investment, clinical progress, and next-generation technologies unlocking hundreds of previously untargeted receptors. With rapid advances in structural biology, computation, and screening, the race is on to validate new GPCRs, understand dynamic activation mechanisms, and develop assays that better predict therapeutic efficacy and guide smarter candidate selection.

Returning as the only industry-led meeting dedicated to GPCR drug discovery, the 5th GPCR-Targeted Drug Discovery Summit features a jam-packed agenda featuring new expert voices, and fresh insights spanning the latest targets, tools, and therapeutic strategies.

Join 80+ GPCR-focused leaders across biopharma to share insights, build collaborations, and accelerate next-generation therapeutics from discovery to clinic.

The scope of the conference covers quite the range of therapeutic indications allowing me to broadly understand current GPCR discovery activities, as well as those drug targets of current therapeutic interest.

Glenn Short, Chief Scientific Officer, Atai Life Sciences

Atai Life Sciences

Participating in this meeting is a valuable opportunity to both learn from and contribute to state-of-the-art discussions on GPCR biology and drug discovery. I see this meeting as a forum for open scientific exchange, new collaborations, and critical dialogue on emerging technologies and ideas that will shape the next generation of GPCR-targeted therapeutics.

William Barnes, Executive Director – Head of GPCR Biology, Iambic Therapeutics

Iambic Therapeutics

This meeting will help pharmacology, medicinal chemistry, and investor leaders with deep interests in GPCR targets to get a “lay of the land” of numerous innovative approaches to measuring, modeling, and modulating GPCR structure and function. How can these insights be leveraged for successful drug discovery?

Chris Dockendorff, Chief Executive Officer & Chief Scientific Officer, Function Therapeutics

Function-Therapeutics-logo-

Explore The Full Event Guide

  • 80+ Attendees
  • 25+ World-Class Speakers
  • 21+ Data-Driven Presentations
  • 7+ Hours of Networking
  • 1 AI & ML Focus Day
69612 - 5th GPCRs-Targeted Drug Discovery Summit

What To Expect

80+

GPCRs Experts in Attendance

25+

World-Class Speakers

21+

Data-Driven Presentations

7+

Hours of Networking

2

Interactive Panel Discussions

1

Scientific Poster Session

Official Partners

69612 - 5th GPCRs-Targeted Drug Discovery Summit
Quick Download

Attending Companies Include

GSK
Eli Lilly
Domain Therapeutics
Confo Therapeutics
logo-abalone
Nabla Bio
Biolexis Therapeutics
Skymab Biotherapeutics
Tectonic Therapeutics
explore the agenda
Explore the Agenda

Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.

Join Biopharma Experts
Join Biopharma Experts

Be part of the hottest conversations with like-minded attendees spanning all stages of drug discovery and make critical connections during our dedicated networking sessions

Partner With Us
Partner With Us

Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.